Drugs that contain Prednisone
1. Rayos patents expiration
RAYOS's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6677326 | HORIZON | Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration |
Mar, 2020
(4 years ago) | |
| US6488960 | HORIZON | Corticosteroid formulation |
Mar, 2020
(4 years ago) | |
| US9040085 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(2 days ago) | |
| US9186332 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(2 days ago) | |
| US8309124 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(2 days ago) | |
| US8394407 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(2 days ago) | |
| US9504699 | HORIZON | Delayed-release glucocorticoid treatment of rheumatoid disease |
Aug, 2027
(3 years from now) | |
| US8168218 | HORIZON | Delayed release tablet with defined core geometry |
Jan, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-128) | Jul 26, 2015 |
Market Authorisation Date: 26 July, 2012
Treatment: Treatment of pulmonary, gastrointestinal and/or rheumatological diseases or conditions by use of delayed release formulations of 1mg or 2mg prednisone; Treatment of rheumatoid arthritis by delayed rel...
Dosage: TABLET, DELAYED RELEASE;ORAL
How can I launch a generic of RAYOS before it's drug patent expiration?
More Information on Dosage
RAYOS family patents
